ClinicalTrials.gg
TerminatedNCT01470131Updated Dec 19, 2018

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

A Phase 3 interventional study of Masitinib and Placebo in Multiple Myeloma, sponsored by AB Science. Terminated at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

From the registry’s dates

  • Primary completion was Jan 2017, 9 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2018.
  • Registered 5 months after the study started (first participant enrolled May 2011, registered Oct 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 377 studies in Multiple Myeloma with a site in France — 73 open to participants now, 137 under way, 49 of them phase 3. Multiple Myeloma · France.

Enrollment
155th of 316
147 · median 138
Started
2011
with 10 others
Phase 3
106 of 377
20 open now
Registered
72nd of 377
by date

Among the 377 studies in Multiple Myeloma with a site in France, this one is the 155th largest by enrollment of the 316 interventional ones that give a count, is one of 11 that started in 2011, is one of 106 in phase 3, and was the 72nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

73 of the 377 studies in Multiple Myeloma with a site in France are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Multiple Myeloma with a site in France, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.

Read the detailed description

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in the treatment of patients with relapsing multiple myeloma who received one previous therapy.

Patients will receive study treatment (masitinib/placebo) with the standard therapy (bortezomib and dexamethazone).

03

Conditions studied

  • Multiple Myeloma

Keywords

  • multiple myeloma
  • relapse
  • second line therapy
  • bortezomib
  • dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with confirmed multiple myeloma requiring systemic therapy. A
  2. Patient with multiple myeloma relapsing according to the International uniform response criteria for multiple myeloma (IMWG 2009/ revised Bladé criteria) to one
  3. Patient with measurable progressive disease

Exclusion criteria

Exclusion Criteria:

  1. Patient with peripheral neuropathy Grade >2
  2. Patient with to bortezomib, boron or dexamethasone
  3. Patient whose disease progressed during or within 60 days of bortezomib treatment or of any other Multiple Myeloma therapy
  4. Patient who received bortezomib within 6 months of randomization to this study
  5. Past discontinuation of bortezomib due to associated grade 3 or higher adverse event
  6. Patient with to high dose of (including ongoing active infection, use of , virosis such as hepatitis, herpes, varicella, herpes zoster)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Masitinib

    Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone

    Drug: Masitinib · Drug: Bortezomib · Drug: Dexamethasone

  • Placebo comparator
    Placebo

    Placebo in combination with Bortezomib and Dexamethasone

    Drug: Placebo · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Masitinib 6 mg/kg/day

    Also known as: AB1010

  • DrugPlacebo

    Matching placebo

  • Standard therapy (cycles of bortezomib)

    Also known as: Velcade

  • Standard therapy (cycles of dexamethasone)

    Also known as: Dexasone

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Time frame: Analysis to be conducted after a minimum of 201 events

Secondary outcomes

  1. Overall Time to Progression

    Time frame: time from the date of randomization to the date of documented progression during the study

  2. Overall Survival

    Time frame: Until death

07

Study locations

13 sites
  • Medical and Surgical Specialists
    Galesburg, Illinois 61401, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Southeastern Medical Oncology Center
    Goldsboro, North Carolina 27534, United States
  • Froedtert & Medical College of Wisconsin-CLCC
    Milwaukee, Wisconsin 53226, United States
  • CHU Estaing
    Clermont Ferrand, France
  • Centre Hospitalier Sud Francilien
    Corbeil-Essonnes, France
  • CH Le Mans
    Le Mans, France
  • Hôpital Universitaire Dupuytren
    Limoges, France
  • Hôpital Ambroise Paré
    Marseille, France
  • Hôpital de l'Hôtel Dieu
    Nantes, France
  • Hôpital Saint Louis
    Paris, France
  • Centre Hospitalier Saint Jean
    Perpignan, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2011 to primary completion in Jan 2017, 68 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2011
First posted
Nov 11, 2011
StartActual
May 2011
Primary completionActual
Jan 4, 2017
CompletionActual
Feb 1, 2017
Results delay requested
Dec 12, 2018
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01470131
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Nov 11, 2011
Start date
May 2011
Primary completion
Jan 4, 2017
Completion
Feb 1, 2017
Last update
Dec 19, 2018

Study contacts

Bertrand Arnulf, MD
principal investigator · Hôpital Saint-Louis, Paris - France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion